Wellington Management Group LLP Acquires 3,291 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Wellington Management Group LLP boosted its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 144,445 shares of the company’s stock after buying an additional 3,291 shares during the period. Wellington Management Group LLP owned approximately 0.09% of Dr. Reddy’s Laboratories worth $10,050,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. GAMMA Investing LLC bought a new position in shares of Dr. Reddy’s Laboratories during the 4th quarter worth about $34,000. CWM LLC grew its stake in shares of Dr. Reddy’s Laboratories by 37.9% in the 4th quarter. CWM LLC now owns 2,174 shares of the company’s stock valued at $151,000 after purchasing an additional 598 shares during the period. Trexquant Investment LP acquired a new position in shares of Dr. Reddy’s Laboratories in the 4th quarter worth approximately $219,000. Blue Trust Inc. lifted its position in shares of Dr. Reddy’s Laboratories by 77.3% during the 4th quarter. Blue Trust Inc. now owns 3,378 shares of the company’s stock worth $227,000 after buying an additional 1,473 shares during the period. Finally, Team Hewins LLC acquired a new stake in Dr. Reddy’s Laboratories in the 4th quarter valued at $239,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Price Performance

Dr. Reddy’s Laboratories stock opened at $75.40 on Friday. Dr. Reddy’s Laboratories Limited has a 52 week low of $61.60 and a 52 week high of $77.72. The firm has a market cap of $12.58 billion, a P/E ratio of 18.71, a P/E/G ratio of 1.61 and a beta of 0.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.92 and a current ratio of 2.58. The business’s fifty day moving average is $71.25 and its two-hundred day moving average is $71.74.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.86 by $0.08. Dr. Reddy’s Laboratories had a net margin of 19.97% and a return on equity of 21.32%. The firm had revenue of $850.00 million for the quarter, compared to analyst estimates of $825.20 million. Equities research analysts forecast that Dr. Reddy’s Laboratories Limited will post 4.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Barclays lifted their price objective on Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, May 8th. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 16th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.